VivoPath is a preclinical screening company, offering our clients discovery and development services for in vivo testing.
VivoPath provides integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting comprehensive program delivers the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process.
VivoPath’s commitment is to provide scientific expertise in drug discovery in order to increase productivity from research into drug development.
Philip D. Lambert Ph.D. Co-Founder and Chief Scientific Officer Phil spent the last 3 years leading the Preclinical Research team at Sirtris Pharmaceuticals. He brings expertise in efficient and predictive preclinical drug discovery to his new role. Over the last ten years, Phil has led in vivo pharmacology groups responsible for both in house and external drug discovery and development in the areas of metabolic and neurodegenerative diseases. He has built teams and screening programs to effectively move compounds through preclinical proof of concept and into the clinic. Phil also held positions at EnVivo Pharmaceuticals, ALS Therapy Development Foundation, Regeneron Pharmaceuticals, GSK and Parke Davis. Phil received his Ph.D. from the University of London and was a faculty member in the Department of Psychiatry at Emory University School of Medicine. He has more than 30 published articles in peer-reviewed journals.
Walter Lunsmann, M.S., MBA Co-Founder and Chief Operating Officer
Walter spent the past 3 years leading the Pharmaceutical Operations and Bioanalytical teams at Sirtris Pharmaceuticals. Walter also led the development project team that successfully delivered the first Sirtris NCE to progress into clinical testing. Over the last 12 years, Walter has led product development groups through all phase of development, from discovery through ANDA filings. Prior to Sirtris, Walter was Associate Director of Formulations for Synta Pharmaceuticals, responsible for Formulation and Manufacturing activities for Synta’s Discovery and Clinical programs in oncology and immune disorders. Walter previously was Study Director and Manager of Formulations for Cardinal Health at the Somerset, NJ Product Development Center, where he led the US Development group for lyophilized drug delivery. Walter received his M.S. in Chemical Engineering from Massachusetts Institute of Technology and his MBA from the Stern School of Business.
